DPP-4 inhibitors like Onglyza, Januvia, Tradjenta, and Nesina need to be “readdressed” by the FDA as they are proven to be associated with an increased death rate.
DPP-4 inhibitors are prescribed for type 2 diabetes; they were very quickly studied, quickly obtained FDA approval, and were quickly distributed via prescription to millions of people.
After the fact Onglyza, Tradjenta, Januvia, and Nesina have been linked to diseases like pancreatic cancer, bladder cancer, liver cancer, and kidney cancer.…People are dying from using these medications and the FDA doesn’t even know why they are killing people.. Imagine that.
TAKE A STAND
ENOUGH! I can’t take this anymore and you shouldn’t either. We are being prescribed toxic medications that have been improperly tested ….and these prescription drugs are literally killing us.
Over 65% of the US adult population has metabolic issues.
IF THE FOLLOWING PARAGRAPH DESCRIBES YOU, DON’T ADD ANY NEW MEDICATIONS UNTIL YOU TAKE CONTROL OF YOUR BODY AND METABOLISM
If you have some of the following medical conditions: hypertension, high cholesterol, high triglycerides, high glucose, non alcohol fatty liver disease, PCOS, pre diabetes, type 2 diabetes, a history of gestational diabetes, are overweight/obese, suffer from GERD and sleep apnea, Alzheimer’s disease, or have had breast, colon, skin, pancreas, ovary, uterine, prostate, or testicular cancer….consider telling your MD you are going to change your lifestyle to The Metabolism Miracle lifestyle.
Get current weight, body measurements, blood pressure, metabolic panel, and lipid profile done and have these measures repeated after 8 weeks of living The Metabolism Miracle plan.
In an 8 week time span, you will have your medications (types or dosages) decreased or eliminated, your lab work and blood pressure will be close to or in your normal range, your weight/body fat/inches will be significantly decreased, and you will be energetic, clear thinking, focused, and feeling younger and healthier than ever. You will not need yet another prescription added to your over-full medicine cabinet.
WHAT TO SAY TO YOUR MD BEFORE HE/SHE PRESCRIBES POTENTIALLY TOXIC MEDICATIONS
“NO THANKS,” I don’t want to add more potentially toxic medication until I try 8 weeks on The Metabolism Miracle plan….. The Metabolism Miracle program is the best prescription you can take to get and stay healthy…without negative side effects”.
YOU have control over your body and what goes into it. Take control of your health now.
BIG PHARMA AND MEDICAL ASSOCIATIONS….I’M ADVOCATING FOR THE PEOPLE AND I DON’T CARE ABOUT YOUR PROFITS.
Following is an article about a class of diabetes medications called DPP-4 inhibitors. Remember Paula Dean was the spokesperson for Januvia? Well, Januvia is a DPP-4 inhibitor.
At the end of this article, I will give you a link to the other article I wrote less than 3 weeks ago when this class of medications was cited for major cancer risk.
New Heart Concerns for Existing Class of Type 2 Medications
Monday, April 27, 2015 by Samuel Grossman, Pharm.D. CDE
Read more: http://www.diabetescare.net/authors/samuel-grossman/new-heart-concerns-for-existing-class-of-type-2-medications?utm_source=DC.net+-+Providers+Newsletter&utm_campaign=ddbee63af5-DC_net_Provider_Newsletter_April_28_2015&utm_medium=email&utm_term=0_4acaa22c03-ddbee63af5-393542347#ixzz3YdUabx00
On April14, the Food & Drug Administration (FDA) panel reviewed the cardiovascular profile of Onglyza by AstraZeneca, approved in 2009, and Nesina by Takeda, approved in 2013. Both medications are members of a class known as DPP-4 inhibitors that includes Januvia, and Tradjenta.
The panel has recommended that Onglyza’s label should include new information about the risk of heart failure. A review of data from the clinical trial SAVOR for patients on Onglyza revealed:
- An increased risk for hospitalization due to heart failure
A review of data for Nesina by the FDA panel did reveal that the number of hospitalizations in patients on Nesina increased due to heart failure; however, the increase in hospitalizations was not statistically significant.
Drug experts believe the FDA will view the risk as a drug class effect and will apply changes to all approved drugs in the DPP-4 inhibitors class. The FDA is expected to follow the advice of its advisory panel–although it is not obliged to do so.
The question is would this recommendation by the FDA panel affect prescribing habits for providers? As a clinician, I believe that the finding by the FDA panel puts providers on an increased alert. If the patient develops heart failure and is being hospitalized, is it a progression of underlying cardiovascular disease or the negligence of the provider who has prescribed a DPP-4 inhibitor?
Although some believe that the new recommendation by the FDA panel will not change the marketing of DPP-4 inhibitors such as Onglyza and Nesina, I beg to differ. If the FDA decides to add this risk-of-heart-failure caution to the package insert, prescribing habits may change. The concern about the risk of worsening cardiac disease or even hospitalization due to heart failure will force providers to reevaluate the risk vs. benefit of DPP-4 inhibitors. No provider wants to be blamed for exacerbating a risk for hospital admission due to heart failure. I believe that if the FDA adapts the recommendation by the FDA advisory panel, it will also bring concerns to patients who are currently on Onglyza or Nesina and have had heart failure.
The possibility remains that many patients will ask their providers to change their medication regimen. Providers will have to reconsider their approach to diabetes therapy based on their experience for their patient population who are currently on DPP-4 inhibitors such as Onglyza and Nesina without any evidence of worsening of heart failure or any hospitalizations due to heart failure.
When DPP-4 inhibitors are not an option for some patients, there are other medication choices to take their place. I believe that providers can prescribe other classes of drugs including GLP-1 agonists or SGLT-2 inhibitors, if they want to diverse patients’ medication regimens. At this point, it remains to be seen how the public and healthcare professionals will react to the ruling by the FDA panel and the subsequent decision by the FDA, but stay tuned for future news.
Dig Diane Kress’ work? Here are links to her books and support site!
The Metabolism Miracle Cookbook: http://www.amazon.com/The-Metabolism-Miracle-Cookbook-Delicious/dp/0738214256/ref=pd_sim_b_1?ie=UTF8&refRID=0DC5FY8CN1D1YH85YNM
The Metabolism Miracle Update: (Brand new!)http://www.amazon.com/Metabolism-Miracle-Update-Revisions-Diabetes-ebook/dp/B00N4IQUF4/ref=sr_1_1?ie=UTF8&qid=1411319947&sr=8-1&keywords=metabolism+miracle+update
The Interactive Support Group for Followers of The Metabolism Miracle and The Diabetes Miracle: http://www.Miracle-Ville.com
***Follow Diane Kress on: Twitter, Facebook, Google +, Pinterest, LinkedIn, and http://www.dianekress.wordpress.com.